Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor for survival. Previous studies have shown that BM angiogenesis does not change following chemotherapy or stem cell transplant. Given its potential antiangiogenic effect, we evaluated if thalidomide therapy would affect the BM microvessel density (MVD). We studied BM angiogenesis in 81 patients with various disease stages treated with thalidomide with or without dexamethasone. MVD was determined as previously described. MVD was compared between pretreatment marrows and those obtained 4-6 months following therapy. The median (range) MVD pretherapy was 28 (2-116) and post-therapy was 15 (3-97). A partial or complete response was seen in 58% of patients, stable disease in 41% and progressive disease in one patient. MVD decreased significantly in responders (median decrease of 12, Po0.001). In contrast, no significant change in MVD was seen in those failing to respond to thalidomide. Unlike the lack of resolution of angiogenesis reported with other therapies, we demonstrate for the first time a significant decrease in microvessels with thalidomide therapy. Although not conclusive, this result lends further support to the hypothesis that angiogenesis is a relevant therapeutic target in myeloma.
Introduction
Multiple myeloma (MM) is characterized by clonal proliferation of plasma cells, resulting in significant morbidity and mortality. The median survival from diagnosis is 3-4 years. 1 Although high-dose chemotherapy and stem cell transplantation improve survival, patients eventually relapse. 2, 3 The need for new therapies has resulted in the introduction of several novel agents in the past few years. Thalidomide was the first among these drugs to demonstrate clinical activity, being effective in all stages of the disease. [4] [5] [6] [7] [8] Although initially evaluated because of its potential antiangiogenic effect, 9 the mechanism of action of thalidomide is unclear. It is likely that thalidomide acts through multiple mechanisms to inhibit growth of myeloma cells. 10 Research over the past two decades has unraveled the importance of abnormal, increased angiogenesis in the development and spread of tumors, both solid tumors and hematological malignancies. [11] [12] [13] In the context of hematological malignancies, increased bone marrow (BM) angiogenesis has been demonstrated in MM, [14] [15] [16] [17] chronic myelocytic leukemia (CML), 18 acute myeloid and lymphocytic leukemias, [19] [20] [21] chronic lymphocytic leukemia (CLL) 22 as well as myelodysplastic syndromes 18 and has been found to have prognostic value. The endothelial cells of the new blood vessels are believed to play an important role in the survival and proliferation of the malignant cells in these disorders, possibly mediated through growth factors and cytokines. Abnormal, high levels of angiogenesis in the BM seem to play an integral role in the pathophysiology of myeloma and is associated with poor prognosis. [14] [15] [16] [17] 23 Additionally, the BM microvessel density (MVD) appears to increase with disease progression from MGUS to active myeloma. 24 We have demonstrated previously that BM angiogenesis does not decrease significantly with conventional or high-dose therapy in myeloma. 25, 26 Prior studies looking at the effect of thalidomide on marrow angiogenesis in myeloma have been limited by small sample size and lack of a uniform time point at which the follow-up assessment is made. 4 Given the importance of the question, we studied the effect of thalidomide therapy on BM MVD in patients with MM treated on a clinical trial at Mayo Clinic.
Methods and materials
A total of 113 patients were treated with thalidomide therapy on a clinical trial conducted at the Mayo Clinic, Rochester, MN, USA. [5] [6] [7] Of these patients, 81 patients (72%) had adequate BM biopsy sections available for evaluation of BM angiogenesis before and after therapy and form the subjects of this study. The post-therapy marrows were performed 4-6 months from start of thalidomide therapy.
Microvessel staining
Paraffin-embedded BM biopsy blocks were used to prepare slides for MVD determination. Immunohistochemical staining for CD34 was performed by a labeled streptavidin-biotin peroxidase method on the ES Ventana automated immunohistochemistry stainer (Ventana Medical Systems, Tucson, AZ, USA) using buffers and detection reagents supplied by the manufacturer. Deparaffinized slides were subjected to a heatinduced epitope retrieval procedure using EDTA for 30 min in a steamer. Slides were cooled for 5 min, rinsed and put on the ES stainer. The primary antibody (anti-CD34; BD Biosciences, clone My10 at a 1/5 dilution) was incubated with tissue sections for 32 min. The AEC (aminoethyl carbazole) detection kit (Ventana Systems) was used for antigen visualization; sections were counterstained with a light hematoxylin and then cover slipped with Kaiseri glycerol jelly (Mayo Medical Laboratories, Rochester, MN, USA). Paraffin sections of well-vascularized tonsil were included with each batch to serve as a positive control; a section stained with nonimmune rabbit immunoglobulin was used as a negative control for each sample tested.
Microvessel density determination
BM angiogenesis was estimated by microscopic evaluation in terms of MVD, as previously described. 24, 26 This technique has been evaluated in the past and found to be reproducible. Slides stained with antibodies to CD34 were first scanned under low power ( Â 100) to identify three hot spots or areas with the greatest number of microvessels. These three areas were then evaluated at Â 400 magnification using a Â 40 objective and a Â 10 ocular lens. To ensure consistency, the same individual using the same microscope (SK) assessed all slides. To eliminate bias, slides were examined under blinded conditions, without prior knowledge of the trial outcome or timing of the BM examination. Large vessels and vessels within the bony spicules and under the periosteum were excluded. Areas of staining without discrete breaks were counted as single vessels. The presence of a lumen or red cells was not required for the identification of microvessels; any highlighted endothelial cell or cell cluster separate from the adjacent microvessels was counted as a distinct vessel. The number of vessels in one Â 400 field was determined for each hot spot; the average was taken as the MVD and expressed as MVD per field. On the basis of the MVD, the patients were grouped into high and low grades. An MVD of more than 20 was classified as high-grade angiogenesis and the rest as low grade.
Therapy
Thalidomide was initially given orally at a dose of 200 mg/day for 2 weeks, and then increased as tolerated to a maximum dose of 800 mg/day for those with smoldering myeloma (SMM) or relapsed myeloma (RMM). Patients with newly diagnosed myeloma (NMM) were treated with thalidomide given at a dose of 200 mg/day orally along with dexamethasone given at a dose of 40 mg/day orally on days 1-4, 9-12 and 17-20 (odd cycles), and 40 mg/day on days 1-4 (even cycles), repeated monthly.
Statistical analysis
Paired t-test was used for comparing the pre-and post-therapy MVD. The change in MVD was assessed separately with respect to the stage of disease at start of therapy as well as the response to therapy. Fisher's exact test was used to compare nominal variables. The predictive value of MVD on response was assessed using logistic regression.
Approval for the study was obtained from the Mayo Institutional Review Board in accordance with federal regulations and the Declaration of Helsinki.
Results and discussion
In all, 81 patients on a clinical trial of thalidomide for newly diagnosed myeloma (NMM, 37), smoldering myeloma (SMM, 26) or relapsed myeloma (RMM, 18) were studied. The median age for the entire group was 62 years and 51 patients (63%) were male.
The median (range) BM MVD at the start of therapy was 28 (2-116) for the entire group. The MVD for those with NMM was 44 (3-116) compared to 34 (3-88) for RMM and 14 (2-87) for SMM. The median post-therapy MVD was 15 (3-97), reflecting a median decrease of 5. The median (range) post-therapy MVD values for the three groups were 16 (5-97), 15 (3-61) and 16 (3-59), respectively. Thalidomide therapy resulted in a partial or complete response in 58% of patients, with 41% having a stable disease and one patient having progressive disease. Among the responding patients, there was a significant decrease in the MVD (median decrease of 12), Po0.001 (Figures 1 and 2 ). There was no significant decrease in the MVD among those with stable disease (median decrease of 1), P ¼ 0.61. The one patient with progressive disease had an increase in MVD of 2. Pretherapy MVD was not predictive of response to thalidomide.
Multiple studies have demonstrated the presence of increased BM angiogenesis in MM. 16, 25, 27 Emerging evidence points toward angiogenesis being an integral part of the pathogenesis of MM. 28, 29 The relationship between BM angiogenesis and prognosis of this disease may be related to the close interaction between the endothelial cell and the malignant plasma cell in the marrow microenvironment. [30] [31] [32] [33] As we have previously demonstrated, there is progressive increase in the BM microvessel density as patients progress from MGUS to active MM. 24 This change is paralleled by an increasing angiogenic potential of the BM in these patients as demonstrated by functional in vitro assays. 29, 34 The increased angiogenic potential is mediated not by malignant plasma cells alone, but also by the marrow stromal cells and the endothelial cells. Others and we have shown that the malignant plasma cells are capable of producing angiogenic factors like VEGF and FGF. 30, 35, 36 These cytokines act through autocrine pathways as well as through paracrine pathways to stimulate plasma cell proliferation and migration. 30, 37 In addition, these angiogenic cytokines are capable of stimulating the endothelial cell precursors in the marrow resulting in new blood vessel formation. In addition to the difference in the malignant plasma cells in myeloma, the endothelial cells from the myeloma marrow also show significant differences in morphology and function compared to their normal counterparts. 31 The finding of increased angiogenesis and its prognostic value have spurred a great deal of interest in the development of agents targeted toward disruption of this vascular network. Thalidomide was initially studied for the treatment of MM because of its potential antiangiogenic effect. 9 Multiple trials have proven its activity in this disease beyond doubt. [4] [5] [6] [7] [8] However, the mechanism of action of this drug in the context of myeloma is not fully understood and probably involves multiple pathways. Prior studies have been unable to demonstrate conclusively a decrease in marrow angiogenesis 25, 26 or angiogenic cytokines 38 with thalidomide therapy. This is probably a result of the limitations of MVD and plasma cytokine levels to serve as a marker of antiangiogenic effect, as well as small sample size and lack of uniform timing of the post-therapy marrow assessment.
In this study, we show that in patients responding to thalidomide therapy, angiogenesis does decrease significantly in the marrow. Although not conclusive of an antiangiogenic effect, this is markedly different from what we have observed with other forms of therapy for myeloma. We have previously demonstrated that BM MVD does not change significantly following conventional chemotherapy or even high-dose therapy with autologous transplantation. Thus the decrease in marrow angiogenesis with thalidomide suggests that an antiangiogenic effect may at least in part explain the mechanism of action of this drug. Preclinical studies in murine myeloma models confirm such a hypothesis. 39, 40 These results assume greater importance with the targeted development of thalidomide analogs, and ongoing studies with other antiangiogenic agents in myeloma such as 2-methoxyestradiol and Bevacizumab. The significance of persistent blood vessels in the marrow is not clear. It is also not clear from these data if thalidomide has resulted in cessation of new vessel formation. Studies have not looked at the functional status of the endothelial cells in these persistent vessels. We hypothesize that the persistent abnormal vasculature is able to sustain malignant plasma cells, leading to the inevitable relapse seen in this disease.
Although MVD decreased significantly in responders, BM MVD had no predictive value on response to thalidomide in this study. We have previously shown that levels of angiogenic cytokines such as VEFG and bFGF also do not predict response to therapy. 38 We are now looking at more sensitive in vitro angiogenesis assays, expression of angiogenic cytokines by quantitative RT-PCR, and microarray analysis to identify predictors of response and further understand the mechanism of action of thalidomide.
